Gilead Sciences, Inc. (GILD) — closed signal from November 2, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 31, 2026.
Predicted vs. what happened
What happened
Reached its target in 82 days.
The thesis — published November 2, 2025
Gilead posted $2.47 per share in profit and HIV drug sales rose 4 percent versus last year. The stock still fell 1.2 percent, which looks more like nerves than a real setback. The recent average price is pointing up, and safer healthcare names are getting attention as rate moves calm down. A 0 to 3 month bounce back toward normal levels seems possible if cancer hurdles are limited and guidance holds steady.
Primary drivers
- Earnings per share beat forecasts, and HIV medicines held up well
- Recent average price trend is tilting upward, hinting at a turn
- Shares slipped on headlines even though profits beat expectations
- More money is moving into safer healthcare stocks as volatility eases
How it played out
GILD: target reached in 82 days
Lyra published GILD at $119 for a short-term window from 2025-11-02 to 2026-01-31. The thesis expected 13% growth and pointed to $2.47 per share in profit, HIV drug sales up 4 percent versus last year, a 1.2 percent stock slip, an upward recent average price trend, calmer rate moves, and demand for safer healthcare names.
Inside the window, the stock reached the $133.59 target in 82 days. It peaked at $142.20 on 2026-01-30, with a 19.5% gain. It ended at $141.95. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.